Anthracycline-containing regimens and anthracycline-free regimens are similar in terms of curative effects for early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer and initial treatment of metastatic breast cancer [17–19]. The gene discussed is ERBB2; the disease is breast carcinoma.